Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
about
Critical evaluation of auditory event-related potential deficits in schizophrenia: evidence from large-scale single-subject pattern classificationExploration of auditory P50 gating in schizophrenia by way of difference waves.Sensory disturbances, inhibitory deficits, and the P50 wave in schizophreniaA placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophreniaCharacterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophreniaAssociation analysis of 94 candidate genes and schizophrenia-related endophenotypes.Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family HistorySensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia.Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometryTranslational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Functional imaging of the hemodynamic sensory gating response in schizophreniaP50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatmentUpregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patientsSpectral decomposition of P50 suppression in schizophrenia during concurrent visual processingDistinct neural generators of sensory gating in schizophrenia.Automatic sensory information processing abnormalities across the illness course of schizophreniaThe use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia.Auditory evoked potential variability in healthy and schizophrenia subjects.Attentional modulation of the P50 suppression deficit in recent-onset and chronic schizophrenia.Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions.Event-related potential abnormalities in schizophrenia: a failure to "gate in" salient information?Profile of auditory information-processing deficits in schizophrenia.Olanzapine improves deficient sensory inhibition in DBA/2 mice.Neurophysiological biomarkers for drug development in schizophrenia.Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measuresReview of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.Functional networks underlying latent inhibition learning in the mouse brain.Generators of the intracranial P50 response in auditory sensory gating.Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.Effect of second-generation antipsychotics on cognition: current issues and future challenges.Distinct M50 and M100 auditory gating deficits in schizophrenia.Genetic bases for endophenotypes in psychiatric disordersAuditory mismatch negativity and repetition suppression deficits in schizophrenia explained by irregular computation of prediction errorDeconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorderInhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of SchizophreniaSuperior temporal gyrus spectral abnormalities in schizophreniaDiagnostic specificity of neurophysiological endophenotypes in schizophrenia and bipolar disorder.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerSensory gating endophenotype based on its neural oscillatory pattern and heritability estimateFailure to find P50 suppression deficits in young first-episode patients with schizophrenia and clinically unaffected siblings
P2860
Q24289175-91167208-61B8-42B4-80FD-9AFDBE5F271FQ25257270-9A285121-52BE-4B61-8985-143392A11140Q27026737-6B0088A0-A2F2-4412-AE08-22E580947E7AQ28287576-0DF8133F-1480-4B30-B770-E88B386DEBCFQ28727584-AD46F80B-8D08-466D-86A0-9B0F9E2326D7Q28732827-7D00EF82-2797-4F64-8121-712D7F4D3BF2Q30359621-A8B7BA01-DE4D-4FB8-AC5F-81057213F385Q30392543-7C5AB20F-3E77-4EFA-B284-A517472C2541Q30404054-A87CEDA8-8AAE-4F57-AE57-3E158141AD7DQ30407039-5A647C7F-C319-49CB-BCC4-96D88C4913EEQ30431837-EDE31920-6578-409F-96D3-E3D3431ED7A4Q30442472-90D3ACD2-46E5-482E-987B-01BF7EF38E0DQ30445339-0F047B75-BB25-4262-8671-781D00DFC01BQ30450089-35E42299-8BE5-4B58-B2AD-A88D011088CBQ30469162-70F4034E-3D19-431F-BF34-3E99BE766F70Q30471850-C5229E4D-3032-42DE-ACA0-D2F7ECD9931CQ30473421-04687C34-699F-48FE-B5A0-A150AAECCBECQ30474629-1ECB7139-28CF-4F75-8AC2-DEE3A83A4F83Q30477282-CD17F92E-D1A2-488E-8368-2835F9B3A960Q30479085-64BF0868-2CF9-4DC7-A6B6-7F37CDF16B8EQ30479816-988D51F7-84BF-44CE-A461-C04FB0F71C9BQ30483719-EA95AE8E-CCCC-4D92-A92A-9E7117ACD925Q30486196-6BA2F67D-8BA2-482A-8B53-0FE403314158Q30486447-B0299FD6-78FF-4D02-A232-B2D60FA118DAQ30491325-DBA255A8-D666-4680-8293-386AB33781F4Q30491339-16E7DC35-6992-40A4-A5BC-6FF1825AE48CQ30493079-FB18A6DA-5231-451B-8976-D7E2941C4D41Q30501117-915FA21A-D795-44A2-8A99-62E8822C7DE9Q31108616-4A4C77C0-F965-4183-904E-054A88371229Q33888153-F93DCB20-91D1-4427-82FE-AB4807DDB186Q34432945-BCADABAA-3171-45E9-B7FD-1584C365B48BQ35236600-239DC60E-A63E-4811-8D30-CA792C4CECD5Q35587074-A6854E25-BCEA-420C-BE05-634A4A697A71Q36646593-F1BC4ED8-1895-40D1-9F36-EDA119033444Q36944287-CBD3DB6E-827C-4191-8BBE-53AC34572EA6Q37199752-F6719AC1-F4A6-44C4-8776-629D320E95C8Q37228278-575D37FA-C75A-4EE1-803C-4E3AEC7842C1Q37258840-D8028FD5-698A-4FA7-AD25-33E7F7E6D904Q37415208-94AA6A7C-8CC0-4888-BEEC-C320E0CBBAA2Q37427114-DA26A3C8-3C72-402B-8817-77C184F6D6E2
P2860
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Normal P50 suppression in schi ...... cal antipsychotic medications.
@en
type
label
Normal P50 suppression in schi ...... cal antipsychotic medications.
@en
prefLabel
Normal P50 suppression in schi ...... cal antipsychotic medications.
@en
P2093
P1476
Normal P50 suppression in schi ...... cal antipsychotic medications.
@en
P2093
B A Clementz
K S Cadenhead
P304
P356
10.1176/APPI.AJP.157.5.767
P407
P577
2000-05-01T00:00:00Z